Co-Authors
This is a "connection" page, showing publications co-authored by RICHARD E CHAMPLIN and ALESSANDRA FERRAJOLI.
Connection Strength
0.416
-
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.
Score: 0.060
-
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893.
Score: 0.054
-
The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Oct; 95(10):1127-1134.
Score: 0.048
-
Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2018 10 11; 379(15):1443-1451.
Score: 0.043
-
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
Score: 0.035
-
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.
Score: 0.034
-
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol. 2015 May 10; 33(14):1557-63.
Score: 0.033
-
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.
Score: 0.030
-
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.
Score: 0.030
-
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011 Oct 15; 117(20):4679-88.
Score: 0.025
-
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23; 116(12):2070-7.
Score: 0.024